X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ASLAN004 (eblasakimab) targets the IL-13 receptor (IL-13R) subunit of the Type 2 receptor, preventing signaling through both interleukin 4 (IL-4) and interleukin 13 (IL-13). It is being evaluated for the treatment of Atopic Dermatitis Patients.
Lead Product(s): Eblasakimab
Therapeutic Area: Dermatology Product Name: ASLAN004
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2024
Details:
ASLAN intends to use the net proceeds to fund new and other ongoing research and development activities, including ASLAN004 (eblasakimab), a novel biologic in development for moderate-to-severe atopic dermatitis.
Lead Product(s): Eblasakimab
Therapeutic Area: Dermatology Product Name: ASLAN004
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 12, 2024
Details:
ASLAN004 (eblasakimab) targets the IL-13 receptor (IL-13R) subunit of the Type 2 receptor, preventing signaling through both interleukin 4 (IL-4) and interleukin 13 (IL-13). It is being evaluated for the treatment of Atopic Dermatitis Patients.
Lead Product(s): Eblasakimab
Therapeutic Area: Dermatology Product Name: ASLAN004
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2024
Details:
ASLAN004 (eblasakimab) is a potential first-in-class monoclonal antibody targeting the IL-13Rɑ1 receptor, being investigated in human tissue model for the treatment of chronic obstructive pulmonary disease.
Lead Product(s): Eblasakimab
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ASLAN004
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2024
Details:
ASLAN004 (eblasakimab) is a potential first-in-class monoclonal antibody targeting the IL-13 receptor that has the potential to deliver a differentiated efficacy and safety profile for the treatment of moderate-to-severe atopic dermatitis (AD).
Lead Product(s): Eblasakimab
Therapeutic Area: Dermatology Product Name: ASLAN004
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2023
Details:
Under the agreement, Zenyaku gains exclusive rights to develop and commercialize ASLAN004 (eblasakimab), a potential first-in-class monoclonal antibody targeting the IL‑13 receptor subunit, in atopic dermatitis (AD) and all other indications in Japan.
Lead Product(s): Eblasakimab
Therapeutic Area: Dermatology Product Name: ASLAN004
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Zenyaku Kogyo
Deal Size: $138.5 million Upfront Cash: $12.0 million
Deal Type: Licensing Agreement June 22, 2023
Details:
ASLAN003 (farudodstat) is a potent oral DHODH inhibitor that suppresses immune cell proliferation and IFNγ secretion by blocking de novo production of pyrimidines required for DNA replication. It is being developed for alopecia areata.
Lead Product(s): Farudodstat
Therapeutic Area: Dermatology Product Name: ASLAN003
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2023
Details:
ASLAN003 (farudodstat) is a potent oral DHODH inhibitor that suppresses immune cell proliferation and IFNγ secretion by blocking de novo production of pyrimidines required for DNA replication. It is being developed for alopecia areata.
Lead Product(s): Farudodstat
Therapeutic Area: Dermatology Product Name: ASLAN003
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2023
Details:
The financing will be used to continue advancing the clinical development of eblasakimab and farudodstat. ASLAN004 is a potential first-in-class antibody targeting the IL-13 receptor in AD with the potential to improve upon current biologics used to treat allergic disease.
Lead Product(s): Eblasakimab
Therapeutic Area: Dermatology Product Name: ASLAN004
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BVF Partners
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Agreement February 24, 2023
Details:
ASLAN004 (eblasakimab) is a potential first-in-class monoclonal antibody targeting the IL-13 receptor that has the potential to deliver a differentiated efficacy and safety profile for the treatment of moderate-to-severe atopic dermatitis (AD).
Lead Product(s): Eblasakimab
Therapeutic Area: Dermatology Product Name: ASLAN004
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
